SPECTRUM PHARMACEUTICALS INC (SPPI) Fundamental Analysis & Valuation

NASDAQ:SPPI • US84763A1088

Current stock price

1.03 USD
0 (0%)
At close:
1.04 USD
+0.01 (+0.97%)
After Hours:

This SPPI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. SPPI Profitability Analysis

1.1 Basic Checks

  • In the past year SPPI has reported negative net income.
  • SPPI had a negative operating cash flow in the past year.
SPPI Yearly Net Income VS EBIT VS OCF VS FCFSPPI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -50M -100M -150M

1.2 Ratios

  • SPPI has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SPPI Yearly ROA, ROE, ROICSPPI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 -100 -200 -300

1.3 Margins

  • SPPI has a Gross Margin of 32.34%. This is in the better half of the industry: SPPI outperforms 75.42% of its industry peers.
  • The Profit Margin and Operating Margin are not available for SPPI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 32.34%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SPPI Yearly Profit, Operating, Gross MarginsSPPI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -200 -400 -600

2

2. SPPI Health Analysis

2.1 Basic Checks

  • SPPI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, SPPI has more shares outstanding
  • The debt/assets ratio for SPPI is higher compared to a year ago.
SPPI Yearly Shares OutstandingSPPI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M
SPPI Yearly Total Debt VS Total AssetsSPPI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M 400M

2.2 Solvency

  • Based on the Altman-Z score of -14.02, we must say that SPPI is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -14.02, SPPI is not doing good in the industry: 86.78% of the companies in the same industry are doing better.
  • SPPI has a Debt/Equity ratio of 1.08. This is a high value indicating a heavy dependency on external financing.
  • SPPI has a worse Debt to Equity ratio (1.08) than 83.05% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.08
Debt/FCF N/A
Altman-Z -14.02
ROIC/WACCN/A
WACC8.97%
SPPI Yearly LT Debt VS Equity VS FCFSPPI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 100M -100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 2.71 indicates that SPPI has no problem at all paying its short term obligations.
  • The Current ratio of SPPI (2.71) is worse than 76.44% of its industry peers.
  • SPPI has a Quick Ratio of 2.38. This indicates that SPPI is financially healthy and has no problem in meeting its short term obligations.
  • SPPI's Quick ratio of 2.38 is on the low side compared to the rest of the industry. SPPI is outperformed by 77.80% of its industry peers.
Industry RankSector Rank
Current Ratio 2.71
Quick Ratio 2.38
SPPI Yearly Current Assets VS Current LiabilitesSPPI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M

4

3. SPPI Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 58.62% over the past year.
EPS 1Y (TTM)58.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • SPPI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 39.88% yearly.
  • Based on estimates for the next years, SPPI will show a very strong growth in Revenue. The Revenue will grow by 98.74% on average per year.
EPS Next Y88.67%
EPS Next 2Y51.91%
EPS Next 3Y39.88%
EPS Next 5YN/A
Revenue Next Year722.64%
Revenue Next 2Y275.85%
Revenue Next 3Y179.1%
Revenue Next 5Y98.74%

3.3 Evolution

SPPI Yearly Revenue VS EstimatesSPPI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M 500M
SPPI Yearly EPS VS EstimatesSPPI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -0.5 -1

4

4. SPPI Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SPPI. In the last year negative earnings were reported.
  • A Price/Forward Earnings ratio of 7.97 indicates a rather cheap valuation of SPPI.
  • Based on the Price/Forward Earnings ratio, SPPI is valued cheaper than 98.98% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 38.88, SPPI is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 7.97
SPPI Price Earnings VS Forward Price EarningsSPPI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SPPI Per share dataSPPI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

  • SPPI's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as SPPI's earnings are expected to grow with 39.88% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y51.91%
EPS Next 3Y39.88%

0

5. SPPI Dividend Analysis

5.1 Amount

  • No dividends for SPPI!.
Industry RankSector Rank
Dividend Yield 0%

SPPI Fundamentals: All Metrics, Ratios and Statistics

SPECTRUM PHARMACEUTICALS INC

NASDAQ:SPPI (7/31/2023, 8:00:02 PM)

After market: 1.04 +0.01 (+0.97%)

1.03

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-10
Earnings (Next)11-08
Inst Owners0.06%
Inst Owner Change0%
Ins Owners1.22%
Ins Owner Change0%
Market Cap211.40M
Revenue(TTM)25.73M
Net Income(TTM)-64.97M
Analysts50
Price Target1.29 (25.24%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)61.99%
Min EPS beat(2)54.61%
Max EPS beat(2)69.36%
EPS beat(4)3
Avg EPS beat(4)34.68%
Min EPS beat(4)-5.49%
Max EPS beat(4)69.36%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)25.37%
Min Revenue beat(2)11.17%
Max Revenue beat(2)39.57%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-34.6%
EPS NQ rev (1m)0%
EPS NQ rev (3m)44.45%
EPS NY rev (1m)78.12%
EPS NY rev (3m)78.12%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)40.01%
Revenue NY rev (1m)47.89%
Revenue NY rev (3m)47.89%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 7.97
P/S 8.22
P/FCF N/A
P/OCF N/A
P/B 7.89
P/tB 7.89
EV/EBITDA N/A
EPS(TTM)-0.36
EYN/A
EPS(NY)0.13
Fwd EY12.54%
FCF(TTM)-0.43
FCFYN/A
OCF(TTM)-0.43
OCFYN/A
SpS0.13
BVpS0.13
TBVpS0.13
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 32.34%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 1.08
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 155.46%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.71
Quick Ratio 2.38
Altman-Z -14.02
F-Score3
WACC8.97%
ROIC/WACCN/A
Cap/Depr(3y)772.71%
Cap/Depr(5y)966.68%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75%
EPS Next Y88.67%
EPS Next 2Y51.91%
EPS Next 3Y39.88%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year722.64%
Revenue Next 2Y275.85%
Revenue Next 3Y179.1%
Revenue Next 5Y98.74%
EBIT growth 1Y50.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y30.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y28.22%
OCF growth 3YN/A
OCF growth 5YN/A

SPECTRUM PHARMACEUTICALS INC / SPPI Fundamental Analysis FAQ

What is the ChartMill fundamental rating of SPECTRUM PHARMACEUTICALS INC (SPPI) stock?

ChartMill assigns a fundamental rating of 2 / 10 to SPPI.


What is the valuation status for SPPI stock?

ChartMill assigns a valuation rating of 4 / 10 to SPECTRUM PHARMACEUTICALS INC (SPPI). This can be considered as Fairly Valued.


Can you provide the profitability details for SPECTRUM PHARMACEUTICALS INC?

SPECTRUM PHARMACEUTICALS INC (SPPI) has a profitability rating of 1 / 10.


How financially healthy is SPECTRUM PHARMACEUTICALS INC?

The financial health rating of SPECTRUM PHARMACEUTICALS INC (SPPI) is 2 / 10.


Is the dividend of SPECTRUM PHARMACEUTICALS INC sustainable?

The dividend rating of SPECTRUM PHARMACEUTICALS INC (SPPI) is 0 / 10 and the dividend payout ratio is 0%.